Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples